Another big win for cell therapy! Adaptimmune has received U.S. FDA accelerated approval for TECELRA® (afamitresgene autoleucel), a novel engineered cell therapy for treating advanced synovial sarcoma in adults. This therapy, the first of its kind for solid tumors, targets patients who have specific HLA types and have previously undergone chemotherapy. Approval is based on overall response rate and duration of response from the SPEARHEAD-1 trial. TECELRA provides a new treatment option after more than a decade for synovial sarcoma patients. For more details, you can read the full release at the following link https://lnkd.in/gp68yd6U
About us
Tune in to the Manufacturing Medicine Podcast, the ultimate podcast for life science professionals who design, build, own, or operate manufacturing facilities. Whether you're an innovator, engineer, builder, executive, or on-the-ground operations, this podcast is your go-to source for cutting-edge insights and industry expertise. Manufacturing Medicine dives deep with the masterminds behind operational readiness and explores the products and services that support building and maintaining compliant life science facilities. We talk to the dedicated people who make manufacturing medicine possible. We discuss best practices, expediting operational readiness, and achieving operational excellence. It's always the people that make the biggest difference. These are the people you can rely on to get the job done, and done right the first time.
- Website
-
www.manufacturingmedicine.com
External link for Manufacturing Medicine
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1 employee
- Type
- Privately Held
- Founded
- 2024
Updates
-
Happy World RNA Day! Today, we celebrate the incredible advancements in RNA research and its transformative impact on medicine and biotechnology. Join us in recognizing the brilliant scientists and their groundbreaking work that continues to unlock new possibilities for treating diseases and improving human health.
-
Exciting News from Moderna! Yesterday, they shipped their first RSV vaccine, marking a significant milestone in the fight against respiratory syncytial virus (RSV). This highly contagious seasonal virus is a leading cause of lower respiratory tract infections, causing between 6,000 to 10,000 deaths each year among adults 65 years and older in the United States. Infants and older adults are especially vulnerable to severe RSV, often requiring hospitalization. The CDC recommends immunizations to protect these at-risk groups, including infants, some young children, and older adults. Moderna’s new vaccine represents a breakthrough in protecting our most vulnerable populations. Here's to more success stories!